(NASDAQ: AKYA) Akoya Biosciences's forecast annual revenue growth rate of 11.01% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.88%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.36%.
Akoya Biosciences's revenue in 2025 is $79,961,000.On average, 1 Wall Street analysts forecast AKYA's revenue for 2025 to be $4,453,873,131, with the lowest AKYA revenue forecast at $4,453,873,131, and the highest AKYA revenue forecast at $4,453,873,131. On average, 1 Wall Street analysts forecast AKYA's revenue for 2026 to be $4,952,627,121, with the lowest AKYA revenue forecast at $4,952,627,121, and the highest AKYA revenue forecast at $4,952,627,121.
In 2027, AKYA is forecast to generate $5,336,667,693 in revenue, with the lowest revenue forecast at $5,336,667,693 and the highest revenue forecast at $5,336,667,693.